Skip to main content

Table 1 Baseline demographics

From: Evaluation of two doses of etoricoxib, a COX-2 selective non-steroidal anti-inflammatory drug (NSAID), in the treatment of Rheumatoid Arthritis in a double-blind, randomized controlled trial

  Placebo N = 118 Etoricoxib 60 mg N = 818 Etoricoxib 90 mg N = 468 Total N = 1404
  n (%) n (%) n (%) n (%)
Gender     
 Female 100 (84.7) 677 (82.8) 395 (84.4) 1172 (83.5)
Age (Years)     
 Mean (SD) 53.6 (11.0) 53.8 (11.9) 54.0 (12.3) 53.8 (12.0)
 Min-Max Age 27 – 80 18 – 83 19 – 84 18 – 84
Race     
 White 85 (72.0) 626 (76.5) 348 (74.4) 1059 (75.4)
 Asian 16 (13.6) 93 (11.4) 55 (11.8) 164 (11.7)
 Multi-racial 10 (8.5) 74 (9.0) 42 (9.0) 126 (9.0)
 Black 4 (3.4) 17 (2.1) 12 (2.6) 33 (2.4)
 Other 3 (2.5) 8 (1.0) 11 (2.4) 22 (1.6)
Duration of RA (Years)     
 Mean (SD) 4.2 (4.3) 5.7 (6.7) 5.8 (6.5) 5.6 (6.5)
ARA Functional Class     
 Class I 18 (15.3) 138 (16.9) 79 (16.9) 235 (16.7)
 Class II 76 (64.4) 535 (65.4) 314 (67.1) 925 (65.9)
 Class III 24 (20.3) 145 (17.7) 75 (16.0) 244 (17.4)
Biologics User 16 (13.6) 113 (13.8) 64 (13.7) 193 (13.7)
Methotrexate User 43 (36.4) 285 (34.8) 170 (36.3) 498 (35.5)
Low-dose Corticosteroid User 25 (21.2) 208 (25.4) 126 (26.9) 359 (25.6)
DMARD User 56 (47.5) 363 (44.4) 219 (46.8) 638 (45.4)
DMARD or Corticosteroid 61 (51.7) 425 (52.0) 247 (52.8) 733 (52.2)